Dr. Tho Lye Mun Oncology

Dr. Tho Lye Mun is among the top oncologist in Kuala Lumpur Malaysia.

Dr Tho Lye Mun completed undergraduate and postgraduate training in Australia and United Kingdom under overseas scholarship programmes. He is qualified in Internal Medicine (MRCP) and holds Fellowship of the Royal College of Radiologists UK in Clinical Oncology (FRCR) as well as full UK specialist accreditation. He then went on to pursue a clinician scientist career gaining a PhD in molecular oncology under the prestigious CRUK/RCR fellowship programme for which he was awarded various prizes including the John Paul Award and the Anne Hollman Medal. He served as an Associate Professor in University Malaya before moving to private practice.

Currently Dr Tho is Vice President of SEAROG (South East Asian Radiation Oncology Group) and is active in developing advanced radiation techniques eg. SRS, SBRT/SABR. He is also Vice President of LCNM (Lung Cancer Network of Malaysia). Dr Tho is an active researcher and has run successful trials in immunotherapy, lung cancer, head and neck cancer and nasopharyngeal cancer. He is a regular invited speaker regionally and internationally.
Awards

1. John Paul Award, Best PhD Student, UK
2. Anne Hollman Medal, Scottish Radiological Society, UK
3. Cancer Research Fellowship, Cancer Research UK (CRUK) / Royal College of Radiologists, UK
4. Best Paper, Annual Scientific Meeting, Royal College of Radiologists, UK
5. Cancer Research Fellowship, Beatson Institute for Cancer Research, UK
6. John Crawford Scholarship for Medicine, Australia
7. ASEAN Scholarship, Singapore

• Gamma knife and Cyberknife SRS
• Intracranial Stereotactic Radiosurgery (SRS)
• Stereotactic Body Radiotherapy (SBRT)
• Stereotactic Ablative Body Radiotherapy (SABR)
• Intensity Modulated Radiotherapy (IMRT)
• Image-Guided Radiotherapy (IGRT)

Lung Cancer. 2019 Oct; 136:65-73.

Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Rajadurai P, Cheah PL, How SH, Liam CK, Annuar MAA, Omar N, Othman N, Marzuki NM, Pang YK, Bustamam RSA, Tho LM.

The Lancet. 2019 May 4;393(10183):1819-1830.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Mok et al KEYNOTE-042 Investigators.

Cancer Medicine. 2015 Aug;4(8):1196-204.

Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. ACHEON Working Group, Kim YC, Ahn JS, Calimag MM, Chao TC, Ho KY, Tho LM, Xia ZJ, Ward L, Moon H, Bhagat A.

Asian Pacific Journal of Cancer Prev. 2015;16(5):1901-6.

Prognostic factors in patients with non-small cell lung carcinoma and brain metastases: a Malaysian perspective. Tang WH, Alip A, Saad M, Phua VC, Chandran H, Tan YH, Tan YY, Kua VF, Wahid MI, Tho LM.

BMC Cancer. 2014 Mar 20;14:212

Closing the global cancer divide–performance of breast cancer care services in a middle income developing country. Lim GC, Aina EN, Cheah SK, Ismail F, Ho GF, Tho LM, Yip Chet al  HPMRS Breast Cancer Study Group.

Targeted Therapy and Immunotherapy for Lung Cancer

www.thestar.com.my/news/nation/2017/11/20/targeted-therapy-and-immunotherapy-for-lung-cancer

Boosting Our Immune System to Fight Cancer

https://www.star2.com/health/2018/09/05/boosting-immune-system-treat-tumours

Profliling the Human Genome

https://www.nst.com.my/lifestyle/heal/2019/09/520171/profiling-human-genome

Facing Up to Breast Cancer

https://www.nst.com.my/lifestyle/heal/2019/10/526132/facing-cancer